Research Grant
[Cite as https://purl.org/au-research/grants/nhmrc/1076356]Researchers: A/Pr Daniel Christ (Principal investigator)
Brief description Therapeutic monoclonal antibodies are among the fastest growing class of drugs with more than $30 billion sales in 2011. Unfortunately, antibodies often display limited stability and a tendency to aggregate. This greatly hinders their development and results in high failure rates of otherwise promising candidates. We have recently identified mutations that render human antibodies resistant to aggregation. Here we apply this technology to a monoclonal antibody candidate developed by a leading pharmaceutical company.
Funding Amount $AUD 421,104.45
Funding Scheme Development Grants
Notes Development Grant
- nhmrc : 1076356
- PURL : https://purl.org/au-research/grants/nhmrc/1076356
